| Immunoglobulin G: a potential treatment to attenuate neuroinflammation following spinal cord injury. | |
| | |
MedLine Citation:
|
PMID: 20437085 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: Spinal cord injury (SCI) is caused by two related but mechanistically distinct events: the primary injury to the spinal cord is caused by a mechanic trauma; the secondary injury is a cascade of cellular and molecular events that exacerbates the initial damage. MATERIALS AND METHODS: Neuroinflammation, an important event in the secondary injury cascade, is critical in the clearance of cellular debris after SCI. However, leukocytes and microglia, recruited to the injury site during neuroinflammation, can exacerbate the initial damage following SCI by secreting reactive oxygen species, matrix-metalloproteinase, and proinflammatory cytokines. Therefore, attenuating the activity of leukocytes and microglia is an attractive therapeutic strategy to reduce the neurological deficit associated with SCI. DISCUSSION: In this regard, immunoglobulin G (IgG) is a potential treatment candidate. IgG has been used clinically to treat autoimmune disease and has been demonstrated to attenuate the activities of leukocytes and microglia. In this review, we discuss the potential use of IgG for SCI based on the current understanding of the immune-modulating mechanism of IgG and the role of neuroinflammation in SCI. |
| | |
Authors:
|
Michael G Fehlings; Dung H Nguyen |
Related Documents
:
|
16972905 - Immune cell migration as a means to control immune privilege: lessons from the cns and ... 11916535 - Alteration of drug biotransformation and elimination during infection and inflammation. 20402965 - Toll-like receptor 4 in cns pathologies. 7783915 - Cytokine production in the central nervous system. 14646515 - Caspase inhibition prevents staurosporine-induced apoptosis in cho-k1 cells. 1321245 - Decreased density of beta-adrenergic receptors on peripheral blood mononuclear cells in... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Journal of clinical immunology Volume: 30 Suppl 1 ISSN: 1573-2592 ISO Abbreviation: J. Clin. Immunol. Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-06-10 Completed Date: 2010-11-01 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8102137 Medline TA: J Clin Immunol Country: Netherlands |
Other Details:
|
Languages: eng Pagination: S109-12 Citation Subset: IM |
Affiliation:
|
Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, ON, Canada. Michael.fehlings@uhn.on.ca |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Anti-Inflammatory Agents / therapeutic use Chemotaxis, Leukocyte Cytokines / secretion Humans Immunoglobulin G / therapeutic use* Immunoglobulins, Intravenous / therapeutic use* Immunologic Factors / therapeutic use* Inflammation Macrophages / physiology Mice Microglia / secretion Models, Immunological Models, Neurological Nerve Regeneration / immunology Neuroprotective Agents / therapeutic use* Spinal Cord Injuries / immunology, pathology, therapy* |
| Grant Support | |
ID/Acronym/Agency:
|
//Canadian Institutes of Health Research |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents; 0/Cytokines; 0/Immunoglobulin G; 0/Immunoglobulins, Intravenous; 0/Immunologic Factors; 0/Neuroprotective Agents |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the disease.
Next Document: Induction of S100B secretion in C6 astroglial cells by the major metabolites accumulating in glutari...